Floatz logo

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta

Histiocytic And Dendritic Cell Neoplasm

Mayo Clinicgene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Histiocytic And Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Ulixertinib
National Cancer Institute (NCI)
Phase 2CCC
Selpercatinib
National Cancer Institute (NCI)
Phase 2CCC
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Panitumumab
Institut de Recherches Internationales Servier
Phase 1/2CCC

View all 11 →

Same molecule, other indications

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta is also rated in:

nonpapillary renal cell carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
renal cell carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
plasma cell myelomaActive
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →